Talphera seeks early NEPHRO CRRT study enrollment close, raising peak sales estimate

Talphera submitted a briefing document to the FDA seeking to close the NEPHRO CRRT study enrollment early and raised nafamostat peak sales estimates for CRRT above $200 million, with cash and investments of $14.2 million as of September 30, 2026.